A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin 5 mg and Empagliflozin 25 mg or Dapagliflozin 10 mg after Oral Administration in Healthy Male Adults

Inclusion Criteria:

• Health Male Volunteers (Age : 19~55 years)
• Body Weight≥55kg, 18.5≤BMI<25.0

Exclusion Criteria:

• galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
• Allergy or Drug hypersensitivity
• Clinically significant Medical History
• AST, ALT > Upper Normal Range*1.25, eGFR<60mL/min/1.73㎡
• Drink during clinical trial period
• Smoking during clinical trial period
• Grapefruit/Caffeine intake during clinical trial period
• No Contraception